Navigation Links
Imagenetix Announces Issuance of New U.S. Patent for the Prevention and Treatment of Periodontal Disease
Date:11/4/2009

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), announced today the issuance of a new U.S. patent (No. 7,612,111). The patent provides intellectual property protection for Imagenetix's 1-TDC early stage drug candidate for the prevention and treatment of periodontal disease.

Commenting on the patent issuance, Mr. William P. Spencer, President of Imagenetix, said, "The issuance is a significant development relating to our novel technology in the therapeutic treatment of periodontal disease and other inflammatory related conditions. Imagenetix now owns a broader range of intellectual property protection on our novel technology with the issuance of this U.S. patent. Through the guidance of Imagenetix's scientists and consultants, who are experts in achieving drug approval in this field, we continue to move forward with our promising drug therapy for the treatment of periodontitis."

Imagenetix's early stage drug candidate (1-TDC) has been studied at Boston University's Department of Periodontology and Oral Biology for the treatment of periodontal disease. In studies published in the Journal of Periodontology, 1-TDC was shown to stop the progression of periodontal disease in a rabbit periodontitis model. Studies at Boston University also demonstrated significant improvement and restoration in tissue and bone health compared to the placebo group.

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis. Imagenetix develops and formulates proprietary over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution. In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners. Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.

             Contact   Imagenetix Investor Relations     William P. Spencer
                       (858)385-2797                Chief Executive Officer
                                                           Imagenetix, Inc.
                                                        Tel: (858) 674-8455

SOURCE Imagenetix, Inc.


'/>"/>
SOURCE Imagenetix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
2. Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascents Neurogenesis Platform
3. BD Announces Results for Fourth Fiscal Quarter and Full Year
4. WebMD Health Corp. Announces Intention To Commence Tender Offer To Repurchase Up To 5,700,000 Shares of its Common Stock
5. Mettler-Toledo International Inc. Announces Webcast of Presentation at Baird Industrial Conference
6. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2009 and to Provide a Business Update
7. West Announces Third Quarter 2009 Results
8. Rigel Announces Third Quarter 2009 Financial Results
9. VIVUS Announces Promotion of Peter Tam to President
10. ATS Medical Announces Third Quarter 2009 Results
11. BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):